A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Clinical trial NCT02252263 · COMPLETED
Trial details
- NCT number
- NCT02252263
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-12-09
- Primary completion
- 2017-10-10
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.